



Published in final edited form as:

*Maturitas*. 2016 May ; 87: 49–60. doi:10.1016/j.maturitas.2016.02.009.

## A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review

Holly N. Thomas, MD MS<sup>\*</sup> and Rebecca C. Thurston, PhD<sup>\*\*</sup>

\*

\*\*

### Abstract

A satisfying sex life is an important component of overall well-being, but sexual dysfunction is common, especially in midlife women. The aim of this review is (a) to define sexual function and dysfunction, (b) to present theoretical models of female sexual response, (c) to examine longitudinal studies of how sexual function changes during midlife, and (d) to review treatment options. Four types of female sexual dysfunction are currently recognized: Female Orgasmic Disorder, Female Sexual Interest/Arousal Disorder, Genito-Pelvic Pain/Penetration Disorder, and Substance/Medication-Induced Sexual Dysfunction. However, optimal sexual function transcends the simple absence of dysfunction. A biopsychosocial approach that simultaneously considers physical, psychological, sociocultural, and interpersonal factors is necessary to guide research and clinical care regarding women's sexual function. Most longitudinal studies reveal an association between advancing menopause status and worsening sexual function. Psychosocial variables, such as availability of a partner, relationship quality, and psychological functioning, also play an integral role. Future directions for research should include deepening our understanding of how sexual function changes with aging and developing safe and effective approaches to optimizing women's sexual function with aging. Overall, holistic, biopsychosocial approaches to women's sexual function are necessary to fully understand and treat this key component of midlife women's well-being.

---

**Corresponding author:** Holly N. Thomas, MD MS, 230 McKee Place Suite 600, Pittsburgh, PA 15213, United States of America, thomashn@upmc.edu.

#### Contributors

HNT conceived idea for manuscript, conducted literature review, interpreted data, prepared initial draft of the manuscript, edited manuscript, submitted manuscript, approved final version to be published.

RCT conceived idea for manuscript, interpreted data, revised manuscript for significant intellectual content, approved final version to be published.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

#### Conflict of interest

None declared.

#### Provenance and peer review

This article has undergone peer review.

## Keywords

sexual function; sexual dysfunction; midlife; menopause; aging; women's health

---

## 1. BACKGROUND

A healthy and satisfying sex life is an important component of overall wellbeing for many midlife women. Multiple studies have shown a strong positive association between sexual function and health-related quality of life (1-4). Sexual problems are common, estimated to affect 22-43% of women worldwide (1, 5, 6). The prevalence of sexual dysfunction peaks at midlife, with 14% of women aged 45-64 reporting at least one sexual problem associated with significant distress (5), yet only 21% of women with persistent sexual problems discuss it with their healthcare provider (7). The aim of this narrative review is to (a) review the definition of sexual dysfunction, (b) understand the theoretical models of female sexual response, (c) examine the major longitudinal studies to understand how and why sexual function changes as women move through midlife, and (d) review the major treatment options for female sexual dysfunction.

The most recent edition of the Diagnostic and Statistical Manual (DSM 5), the major manual of psychiatric and behavioral disorders, states that sexual dysfunctions “are a heterogeneous group of disorders that are typically characterized by a clinically significant disturbance in a person’s ability to respond sexually or to experience sexual pleasure.” (8) As such, “female sexual dysfunction” is an umbrella term for four distinct disorders recognized in the DSM 5: Female Orgasmic Disorder, Female Sexual Interest/Arousal Disorder (FSIAD, which encompasses what were previously termed Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder in the DSM IV), Genito-Pelvic Pain/Penetration Disorder (which encompasses what were previously termed vaginismus and dyspareunia), and Substance/Medication-Induced Sexual Dysfunction. To diagnose any one of these disorders, the symptoms must be (a) present at least 6 months, (b) cause *clinically significant distress* in the individual [not solely in the individual’s sexual partner(s)], and (c) not be better explained by another issue, such as relationship distress or other stressors (8).

In contrast to a sole focus on sexual dysfunction, researchers and healthcare providers should consider overall sexual health to help women maintain a satisfying sex life. The World Health Organization defines overall sexual health as “a state of physical, emotional, mental and social well-being in relationship to sexuality; it is not merely the absence of disease, dysfunction or infirmity. Sexual health requires a positive and respectful approach to sexuality and sexual relationships, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, discrimination and violence.” (9) The focus is not just on physical sexual function – are the genitals “working” – but whether the individual can be fulfilled and satisfied in their physical, emotional, and social experiences with sex.

## 2. MEASUREMENT OF SEXUAL FUNCTION

A number of instruments have been developed to measure female sexual function, some of which are summarized in Table 1. A more comprehensive review of available measures was

published in 2009 (10). The most widely used instrument recently has been the Female Sexual Function Index (FSFI), a 19-item scale with six domains: desire, arousal, lubrication, orgasm, pain, and satisfaction. Questions are graded on a Likert scale, and domains are weighted and summed to give a total score ranging from 2 to 36, with a cutoff of less than 26.55 suggesting sexual dysfunction (11). Subsequent research has shown that mean scores on the FSFI tend to be lower in midlife and older women (12). Some have advocated for a scoring adjustment in this population (13), calling into question conceptions of normative or ideal sexual function in aging women. The FSFI has been validated in multiple languages, across age groups, and for multiple sexual disorders. Another commonly used instrument in sexual function studies is the Female Sexual Distress Scale – Revised (FSDS-R), which measures sexually related distress using 13 items (14). As discussed above, a diagnosis of sexual dysfunction requires significant sexually related distress in addition to a sexual problem or complaint. Validation studies for the FSDS-R have focused on women with what was previously termed Hypoactive Sexual Desire Disorder (14, 15).

### 3. MODELS OF FEMALE SEXUAL RESPONSE

Theoretical models of women's sexual response can provide a framework for understanding female sexual dysfunction. The Masters-Johnson model was one of the first, developed in the 1960s, and applies to both men and women (Figure 1)(16). According to this model, sexual response progresses predictably and linearly from excitement to plateau, orgasm, and resolution. The main focus of this model is on physical response of the genitals. Helen Singer Kaplan, a psychologist and sex therapist, noted that many individuals had problems with sexual desire, denoting the importance of desire to sexual response. In the 1970s she modified the Masters-Johnson model to a three-phase model of desire, excitement, and orgasm (Figure 2) (17).

In 2000, Rosemary Basson and colleagues proposed an alternative circular model of female sexual response (Figure 3)(18). This model has several distinguishing features. First, spontaneous desire (or "sexual drive") on the part of the woman is not always the starting point for sexual activity. Instead, desire may result from feelings of emotional intimacy with one's partner that lead the woman to seek out sexual stimulation or to be more receptive to sexual stimulation initiated by her partner. Second, this model emphasizes that sexual stimuli often *precede* physical arousal and desire, and sexual arousal and desire often co-occur. This perspective lies in contrast to the Masters-Johnson-Kaplan model, in which desire always precedes arousal. Qualitative research suggests that for many women, the concepts of desire (the interest in or urge for sexual activity) and arousal (sexual excitement and pleasure) are difficult to distinguish; when asked to describe sexual desire, many women use language that describes genital sexual arousal (19-21). Finally, the Basson model acknowledges that both physical as well as emotional satisfaction are important outcomes of engaging in sexual activity. This physical and emotional satisfaction can lead to higher emotional intimacy, which in turn can lead to greater receptivity and seeking out of sexual stimuli, hence the circular model.

There has been debate regarding which model best reflects the experiences of women. In a study of 133 women (22), most of whom were in their 40s and 50s, 30% endorsed the

Masters-Johnson model, 27% endorsed the Masters-Johnson-Kaplan model, and 29% endorsed the Basson model. The remaining 14% of women did not endorse any model. Women who had FSFI scores falling into the “dysfunctional” range and postmenopausal women were more likely to endorse the Basson model.

A subsequent study of 404 women with a mean age of 35 found that women both with and without sexual dysfunction felt the Masters-Johnson-Kaplan model more accurately represented their sexual response. However, when the researchers modified the Basson model to combine the responsive desire and sexual arousal phases, women with sexual dysfunction were more likely to endorse the Basson model than the Masters/Johnson/Kaplan model (23). Both these studies have been criticized for using the FSFI to classify women with sexual dysfunction, as the FSFI itself is rooted in the Masters-Johnson-Kaplan model (24).

It is likely that there are aspects of both models that are useful to women, healthcare providers, and researchers. The Masters-Johnson-Kaplan model is useful for conceptualizing the physical aspects of female sexual function and dysfunction, whereas the Basson model is useful for understanding the interplay between emotional, interpersonal, and physical aspects of sexual response. Notably, most recent epidemiologic studies and clinical trials exclusively use the FSFI, which places a greater emphasis on the physical aspects of sexual function, as an outcome measure. Researchers should include an evaluation of the psychosocial aspects of sexual function reflected in the Basson model, such as emotional intimacy, in studies of female sexual dysfunction, particularly since women with sexual dysfunction appear to be more likely to endorse this model. One such scale is the Personal Assessment of Intimacy in Relationships Scale (25). A multidimensional assessment of physical, interpersonal, and emotional aspects of sexual function will enhance the current state of the science on women’s sexual function.

#### 4. CHANGES IN SEXUAL FUNCTION OVER THE MENOPAUSE TRANSITION

One major question in the field of women’s sexual health has been, “How and why does sexual function change as women progress through midlife and the menopause transition?”. Several large longitudinal studies have attempted to answer this question (Table 2). Longitudinal studies are better suited to addressing changes in sexual function and satisfaction over time than cross-sectional studies. Longitudinal studies that follow a cohort of women over time allow comparison of a woman’s sexual function to herself, provide more effective control of between-subject confounds and cohort effects, and allow characterization of trajectories in sexual function over time.

Most studies show that sexual function worsens with advancing menopause status, even when adjusting for age (26-31). Vaginal dryness appears to play a key role in changing sexual function during the menopause transition (29, 30). In contrast, three smaller longitudinal studies that only assessed sexual function using one or two questions found that sexual activity and reports of desire were stable over time during midlife (32-34).

Among the studies that used a multidimensional assessment of sexual function, there were differences regarding *which* aspects of sexual function were most affected by menopause. In

the second wave of the Massachusetts Women's Health Study, sexual desire, but not satisfaction, frequency, arousal, orgasm, or pain, were negatively affected by the menopause transition (26). The Melbourne Women's Midlife Health project found that all domains of sexual function, including responsiveness, frequency, libido, and pain, worsened with advancing menopause status (27). The Penn Ovarian Aging Study found the sharpest decline in the lubrication domain (28), while the Study of Women's Health Across the Nation (SWAN) noted only desire and pain worsened with menopause, but not frequency, arousal, importance of sex, or overall satisfaction (30). Notably, 3 out of 4 of these studies noted declines in sexual desire during the menopause transition.

A consistent theme throughout these studies, however, is the importance of other factors aside from menopause status to sexual function. Many studies note a positive correlation between overall physical health and sexual function (26, 30, 31, 34). Availability of a partner is also significantly related to better sexual function (26-28, 30, 31, 34). Stress or mood symptoms, such as depression and anxiety, are correlated with lower sexual function across several studies (26, 28, 29). Finally, indicators of higher socioeconomic status are associated with better midlife sexual function in some studies (30, 34, 35).

These studies all face similar challenges. One challenge is the measurement of sexual function. These studies used different instruments to assess female sexual function, and few used validated instruments. Another challenge is distinguishing sexual problems or complaints from overt sexual dysfunction. Many women will report a sexual complaint, such as vaginal dryness, on a questionnaire. However, a diagnosis of sexual dysfunction requires significant distress due to the sexual complaint. None of these longitudinal studies assessed sexually-related distress. Finally, female sexual function is a complex biopsychosocial phenomenon, and a complete understanding of women's sexual function requires assessment of biologic, sociocultural, psychological, and interpersonal factors.

In summary, most of the larger longitudinal studies using multidimensional assessments of sexual function do suggest that advancing menopause status has a negative effect on sexual function. However, psychosocial variables also play an extremely important role in midlife women's sexual function. Loss of a partner, changes in the quality of the relationship with one's partner, and worsening mood symptoms are typically associated with worse sexual function.

Taken together, these findings remind us that the biopsychosocial approach is necessary for understanding and treating sexual dysfunction in midlife women (Figure 4). The biopsychosocial approach recognizes that biologic, psychological, interpersonal, and sociocultural factors can all affect female sexual function, and these factors interact with each other in a dynamic system over time. *Biologic* factors may include hormonal changes that affect libido or medical/anatomical problems that affect genital sexual response. *Psychological* factors includes mood symptoms, like depression or anxiety, or negative behaviors such as critical self-monitoring during sexual activity. Some examples of *interpersonal factors* include general satisfaction in the woman's relationship with her partner, which is closely tied to overall sexual satisfaction, as well as quality of communication in the relationship. Finally, some *sociocultural* factors to consider include

the woman's attitudes about menopause and aging, as well as religious, cultural, and other social values regarding sex. Researchers and healthcare providers for women should consider all these factors when addressing female sexual function.

One outcome that may be more important to women than the physical aspects of sexual function is overall satisfaction with sex. Sexual satisfaction has been less well-studied than sexual function. In SWAN, emotional and physical satisfaction with sex did not significantly change with advancing menopause status, although current and former hormone therapy users reported higher physical pleasure compared to premenopausal women (30). Many of the predictors of increased satisfaction in SWAN were psychosocial as opposed to physical; availability of a partner (especially a new partner), higher ratings of the importance of sex, fewer mood symptoms, and more positive attitudes about aging were associated with better emotional and physical sexual satisfaction. A cross-sectional analysis of 1345 women in the second Midlife in the United States (MIDUS 2) study likewise found that menopause status was not associated with overall sexual satisfaction, but psychosocial variables, including relationship satisfaction, communication with one's partner, and importance of sex were associated with overall sexual satisfaction (36). These findings suggest that while some aspects of physical sexual function may decline during midlife, sexual satisfaction appears to be stable. This discrepancy between function and satisfaction may be explained by the fact that midlife women adapt to physical changes (by using sexual aids, trying varying types of sex, etc.) in order to maintain a satisfying sex life with aging.

## 5. TREATMENTS FOR FEMALE SEXUAL DYSFUNCTION

In order to help women maintain a satisfying sex life as they move through midlife and beyond, treatment of sexual dysfunction is sometimes required. When a woman presents to her healthcare provider with a sexual complaint, assessing menopause status and symptoms is essential, with a particular focus on vaginal dryness and pain issues. However, interpersonal, psychological, and sociocultural factors must be addressed as well. Some women may initially report no sexual concerns when first questioned, but if a woman is allowed time and a supportive listening environment, a clearer picture of precipitating and maintaining factors may emerge. For example, a woman may initially report her main problem is that it takes longer to orgasm. However, on further discussion, she reveals that her male partner is having difficulty maintaining erections, but she is hesitant to discuss trying non-penetrative forms of sexual activity at the risk of upsetting her partner. Issues around relationship quality and communication can affect sexual function in couples, even if a "relationship problem" is not readily evident. These issues may be readily amenable to improvement with limited psychoeducational interventions or counseling.

When addressing a new sexual complaint, a thorough history using a biopsychosocial approach should be undertaken, including assessment of any current or past psychiatric disorders; medication use and health problems; a history of emotional, physical, or sexual abuse; beliefs and attitudes regarding sex, menopause, and aging; and body image concerns. Particular attention should be paid to symptoms of depression, anxiety, and sleep problems, all of which are common during the menopause transition (37-48). Providers should inquire about alcohol or drug use, as substance use disorders are also associated with sexual

dysfunction (49). Any health or sexual problems affecting the woman's sexual partner(s) should also be explored. Providers should inquire about relationship discord or communication issues, and if present, recommend therapy with a therapist certified by the American Association of Sexuality Educators Counselors and Therapists (AASECT).

Women presenting for a new sexual problem should be seen by their primary healthcare provider for a comprehensive physical examination, including a pelvic examination. Medical problems and medications should be reviewed for any that may potentially contribute to sexual dysfunction (Table 3), and treatment of the underlying condition or adjustments in medication regimens should be undertaken if possible. Antidepressants, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs), are commonly implicated, particularly in disorders of arousal and orgasm (50-55). Bupropion is an antidepressant that appears to have few sexual side effects (55-58). There is also evidence that bupropion (59-61) and, to a lesser extent, sildenafil (62), are effective for treating antidepressant-induced sexual dysfunction in women, although some conflicting evidence exists (63, 64). Screening for intimate partner violence should take place, and if positive, appropriate referrals and resources should be provided.

Treatments depend on the specific disorder(s) in question. Treatment options for specific sexual dysfunctions are summarized in Table 4. Providers should recognize that women often have more than one sexual complaint; treatment should be individualized to target the primary problem, but should be supplemented by treatment of other problems as needed. General lifestyle counseling that may be useful for all types of female sexual dysfunction include recommending setting aside time for connecting with one's partner, increasing the woman's exposure to sexual stimuli such as erotic literature or films, encouraging maintenance of a healthy weight and ensuring adequate physical activity and sleep, enhancing skills for coping with stress, and recommending books women can use for self education. Some major titles include *Becoming Orgasmic* (65), *Getting the Sex You Want* (66), *Naked at Our Age* (67), and *Come as You Are* (68). A book that may be helpful for male partners is *She Comes First* (69). The websites for the North American Menopause Society ([menopause.org](http://menopause.org)) and MiddlesexMD ([middlesexmd.com](http://middlesexmd.com)), an online resource spearheaded by a certified menopause healthcare physician, also contain useful, evidence-based information for patients regarding menopause and sex.

Some providers use testosterone for the treatment of FSIAD, and there is a growing body of evidence supporting its efficacy, at least in the short term (70, 71). However, this treatment is not FDA-approved, and there remains concern regarding side effects, including hirsutism, dyslipidemia, and given the physiologic conversion of androgens to estrogens, possible estrogen-related side effects (including venous thromboembolism and breast or endometrial cancer) (71-74). A black box warning was recently added to testosterone products marketed to men after a longitudinal study suggested a 30% higher risk of adverse cardiovascular outcomes (75), although this study has been criticized due to methodology concerns (76-79), and whether it is generalizable to women is unknown. Finally, it appears supraphysiological serum testosterone levels may be necessary to yield any benefit on sexual desire and arousal (80, 81). The use of compounded testosterone products for transdermal use is on the rise, but

these products are not regulated and amount of testosterone in the product can be highly inconsistent (82). Hormone therapy (estrogen with or without progesterone) does not appear to have a significant impact on sexual function, with the exception of vaginal estrogen in women with genitourinary syndrome of menopause (83).

## 6. FUTURE DIRECTIONS

Much advancement has been made over the past 5 decades in our understanding of female sexual function and dysfunction. We now have clearer definitions of female sexual disorders that better reflect the lived experience of women; models of female sexual response that reflect both the physical and emotional aspects of a women's sexual experience; a clearer picture of how menopause affects sexual function; and new and emerging treatment options. However, there is still much work to be done.

First, we need a deeper understanding of women's typical sexual activity and sexual function patterns during midlife and beyond, including how sex may or may not change with aging, and why some women are distressed by changes in sexual function while others are not. Clarifying longitudinal patterns of change in sex and associated distress in large groups of midlife women will help us define what are normative changes over time versus what are "dysfunctions." While taking women's sexual concerns seriously, researchers and clinicians must also be mindful not to pathologize all age-related changes in sexual function, or we risk labeling healthy women as "dysfunctional." In fact, some have expressed concern that the concept of "female sexual dysfunction" has been overstated – the "making of a disease" in order to develop and sell medications (84-87). An emphasis on women's sexual satisfaction and complete assessment of the biopsychosocial contributors to sexual function may help avoid over-medicalization of age-related changes. Understanding longitudinal patterns in sexual function is essential to ensuring that we can confidently educate our patients regarding what to expect as they grow older and to optimally tailor treatments for sexual dysfunctions.

Second, we need to continue to develop safe and effective treatments for female sexual dysfunction, particularly for midlife and older women. Postmenopausal women have been excluded from many of the trials of pharmaceutical medications. Additionally, concerns about side effects and medication interactions are increased in an older population. Behavioral treatment approaches have shown promise for the treatment of several types of female sexual dysfunction. However, these treatments are not typically widely available (88-92). Future research should focus on ensuring that these behavioral interventions are optimized to meet the needs of midlife and older women, on targeting the outcomes that are most important in this population, and on exploring ways to disseminate behavioral interventions more widely. Finding ways to integrate these behavioral interventions into primary care and general gynecology practices will ensure that they reach the greatest number of women in need.

In summary, sexual dysfunction is highly prevalent among midlife women and is associated with lower quality of life, and sexual function declines over the menopause transition for many women. Research regarding theoretical models of female sexual response as well as



longitudinal cohort data reveals that psychosocial factors, such as relationship satisfaction and importance of sex, are key to women's sexual function at midlife. Both researchers and healthcare providers can benefit from a biopsychosocial approach to women's sexual function. By addressing *all* aspects of women's sexual function, researchers and healthcare providers can better understand and improve this key component of midlife women's well-being.

## ACKNOWLEDGEMENTS

This work was supported by supported by the Agency on Healthcare Quality and Research (K12HS022989, PI: Wishwa Kapoor) and the National Institute of Health's National Heart, Lung, and Blood Institute and National Institute on Aging (K24123565, PI: Thurston). None of these sponsors had any role in the study design, data collection, data analysis, interpretation of data, writing of the manuscript, or decision to submit the manuscript for publication.

### Funding

All organizations that funded relevant author research are mentioned in the Acknowledgements.

## REFERENCES

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. *JAMA*. 1999; 281(6):537–44. [PubMed: 10022110]
2. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). *Menopause*. 2006; 13(1):46–56. [PubMed: 16607098]
3. Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. *Value Health*. 2009; 12(5): 763–72. [PubMed: 19192259]
4. Ventegodt S. Sex and the quality of life in Denmark. *Arch Sex Behav*. 1998; 27(3):295–307. [PubMed: 9604118]
5. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. *Obstet Gynecol*. 2008; 112(5):970–8. [PubMed: 18978095]
6. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *Int J Impot Res*. 2005; 17(1):39–57. [PubMed: 15215881]
7. Mercer CH, Fenton KA, Johnson AM, Wellings K, Macdowall W, McManus S, et al. Sexual function problems and help seeking behaviour in Britain: national probability sample survey. *BMJ*. 2003; 327(7412):426–7. [PubMed: 12933730]
8. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders : DSM-5*. 5th ed. American Psychiatric Association; Washington, D.C.: 2013. American Psychiatric Association. DSM-5 Task Force.
9. Organization, WH. *Defining sexual health: Report of a technical consultation on sexual health*. World Health Organization; Geneva, Switzerland: 2006. p. 35
10. Jeffery DD, Tzeng JP, Keefe FJ, Porter LS, Hahn EA, Flynn KE, et al. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. *Cancer*. 2009; 115(6):1142–53. [PubMed: 19195044]
11. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. *J Sex Marital Ther*. 2005; 31(1):1–20. [PubMed: 15841702]
12. Thomas HN, Chang CC, Dillon S, Hess R. Sexual activity in midlife women: importance of sex matters. *JAMA Intern Med*. 2014; 174(4):631–3. [PubMed: 24515395]

13. Dargis LT G, Cadieux J, Villeneuve L, Preville M, Boyer R. Validation of the Female Sexual Function Index (FSFI) and presentation of norms in older women. *Sexologies*. 2012; 21:126–31.
14. Derogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. *J Sex Med*. 2008; 5(2):357–64. [PubMed: 18042215]
15. DeRogatis L, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress Scale-Revised cover the feelings of women with HSDD? *J Sex Med*. 2011; 8(10):2810–5. [PubMed: 21771282]
16. Masters, WHJV. *Human sexual response*. Little, Brown & Co; Boston: 1966.
17. Kaplan HS. *Disorders of Sexual Desire*: Simon and Schuster. 1979
18. Basson R. The female sexual response: a different model. *J Sex Marital Ther*. 2000; 26(1):51–65. [PubMed: 10693116]
19. Laan E, Both S. What makes women experience desire? *Feminism & Psychology*. 2008; 18(4): 505–14.
20. Brotto LA, Heiman JR, Tolman DL. Narratives of desire in mid-age women with and without arousal difficulties. *J Sex Res*. 2009; 46(5):387–98. [PubMed: 19291528]
21. Graham CA, Sanders SA, Milhausen RR, McBride KR. Turning on and turning off: a focus group study of the factors that affect women's sexual arousal. *Arch Sex Behav*. 2004; 33(6):527–38. [PubMed: 15483367]
22. Sand M, Fisher WA. Women's endorsement of models of female sexual response: the nurses' sexuality study. *J Sex Med*. 2007; 4(3):708–19. [PubMed: 17498106]
23. Giles KR, McCabe MP. Conceptualizing women's sexual function: linear vs. circular models of sexual response. *J Sex Med*. 2009; 6(10):2761–71. [PubMed: 19686428]
24. Hayes RD. Circular and linear modeling of female sexual desire and arousal. *J Sex Res*. 2011; 48(2-3):130–41. [PubMed: 21409710]
25. Moore KA, McCabe MP, Stockdale JE. Factor analysis of the Personal Assessment of Intimacy in Relationships Scale (PAIR): Engagement, communication and shared friendships. *Sexual and Marital Therapy*. 1998; 13(4):361–8.
26. Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? *Menopause*. 2000; 7(5):297–309. [PubMed: 10993029]
27. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. *Climacteric*. 2004; 7(4):375–89. [PubMed: 15799609]
28. Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M. Hormones and sexuality during transition to menopause. *Obstet Gynecol*. 2007; 109(4):831–40. [PubMed: 17400843]
29. Mishra G, Kuh D. Sexual functioning throughout menopause: the perceptions of women in a British cohort. *Menopause*. 2006; 13(6):880–90. [PubMed: 17003739]
30. Avis NE, Brockwell S, Randolph JF Jr, Shen S, Cain VS, Ory M, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. *Menopause*. 2009; 16(3):442–52. [PubMed: 19212271]
31. Woods NF, Mitchell ES, Smith-Di Julio K. Sexual desire during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. *J Womens Health (Larchmt)*. 2010; 19(2):209–18. [PubMed: 20109116]
32. George LK, Weiler SJ. Sexuality in middle and late life. The effects of age, cohort, and gender. *Arch Gen Psychiatry*. 1981; 38(8):919–23. [PubMed: 7259426]
33. Hallstrom T, Samuelsson S. Changes in women's sexual desire in middle life: the longitudinal study of women in Gothenburg. *Arch Sex Behav*. 1990; 19(3):259–68. [PubMed: 2360875]
34. Koster A, Garde K. Sexual desire and menopausal development. A prospective study of Danish women born in 1936. *Maturitas*. 1993; 16(1):49–60. [PubMed: 8429803]
35. Prairie BA, Scheier MF, Matthews KA, Chang CC, Hess R. A higher sense of purpose in life is associated with sexual enjoyment in midlife women. *Menopause*. 2011; 18(8):839–44. [PubMed: 21659908]

36. Thomas HN, Hess R, Thurston RC. Correlates of Sexual Activity and Satisfaction in Midlife and Older Women. *Ann Fam Med*. 2015; 13(4):336–42. [PubMed: 26195678]
37. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. *Climacteric*. 2001; 4(3):243–9. [PubMed: 11588948]
38. Baker A, Simpson S, Dawson D. Sleep disruption and mood changes associated with menopause. *J Psychosom Res*. 1997; 43(4):359–69. [PubMed: 9330235]
39. Freedman RR, Roehrs TA. Sleep disturbance in menopause. *Menopause*. 2007; 14(5):826–9. [PubMed: 17486023]
40. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause*. 2003; 10(1):19–28. [PubMed: 12544673]
41. Stone AB, Pearlstein TB. Evaluation and treatment of changes in mood, sleep, and sexual functioning associated with menopause. *Obstet Gynecol Clin North Am*. 1994; 21(2):391–403. [PubMed: 7936551]
42. Sagsoz N, Oguzturk O, Bayram M, Kamaci M. Anxiety and depression before and after the menopause. *Arch Gynecol Obstet*. 2001; 264(4):199–202. [PubMed: 11205708]
43. Schnatz PF, Whitehurst SK, O'Sullivan DM. Sexual dysfunction, depression, and anxiety among patients of an inner-city menopause clinic. *J Womens Health (Larchmt)*. 2010; 19(10):1843–9. [PubMed: 20677995]
44. Cheng MH, Hsu CY, Wang SJ, Lee SJ, Wang PH, Fuh JL. The relationship of self-reported sleep disturbance, mood, and menopause in a community study. *Menopause*. 2008; 15(5):958–62. [PubMed: 18779680]
45. Young T, Rabago D, Zgierska A, Austin D, Laurel F. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. *Sleep*. 2003; 26(6):667–72. [PubMed: 14572118]
46. Bromberger JT, Matthews KA, Schott LL, Brockwell S, Avis NE, Kravitz HM, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). *J Affect Disord*. 2007; 103(1-3):267–72. [PubMed: 17331589]
47. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. *Arch Gen Psychiatry*. 2006; 63(4):375–82. [PubMed: 16585466]
48. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. *Arch Gen Psychiatry*. 2006; 63(4):385–90. [PubMed: 16585467]
49. Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. *J Psychoactive Drugs*. 2001; 33(3):223–32. [PubMed: 11718315]
50. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol*. 2009; 29(3):259–66. [PubMed: 19440080]
51. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. *Ann Pharmacother*. 2002; 36(10):1577–89. [PubMed: 12243609]
52. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. *J Clin Psychiatry*. 2002; 63(4):357–66. [PubMed: 12000211]
53. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. *J Clin Psychiatry*. 2000; 61(4):276–81. [PubMed: 10830148]
54. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. *J Clin Psychiatry*. 2001; 62(Suppl 3):10–21. [PubMed: 11229449]
55. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. *Clin Pharmacol Ther*. 1997; 61(4):476–87. [PubMed: 9129565]

56. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. *Clin Ther.* 1999; 21(4):643–58. [PubMed: 10363731]
57. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. *Clin Ther.* 2001; 23(7):1040–58. [PubMed: 11519769]
58. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. *J Clin Psychiatry.* 2006; 67(5):736–46. [PubMed: 16841623]
59. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. *J Clin Psychiatry.* 2004; 65(1):62–7. [PubMed: 14744170]
60. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. *J Clin Psychiatry.* 1998; 59(3):112–5. [PubMed: 9541153]
61. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. *J Clin Psychiatry.* 2001; 62(3):185–90. [PubMed: 11305705]
62. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. *JAMA.* 2008; 300(4):395–404. [PubMed: 18647982]
63. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. *J Clin Psychiatry.* 2005; 66(7):844–8. [PubMed: 16013899]
64. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. *Am J Psychiatry.* 2001; 158(5):805–7. [PubMed: 11329407]
65. Heiman, J.; LoPiccolo, J. *Becoming orgasmic: A sexual and personal growth program for women.* Simon and Schuster; New York, NY: 1987.
66. Leiblum, S.; Sachs, J. *Getting the sex you want: A woman's guide to becoming proud, passionate, and pleased in bed.* ASJA Press; Lincoln, Nebraska: 2002.
67. Price, J. *Naked at our age: Talking out loud about senior sex.* Seal Press; Berkeley, California: 2011.
68. Nagoski, E. *Come as you are: The surprising new science that will transform your sex life.* Simon & Schuster; New York, NY: 2015.
69. Kerner, I. *She comes first: The thinking man's guide to pleasuring a woman.* Harper Collins; New York, NY: 2009.
70. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. *J Sex Med.* 2012; 9(4):1134–48. [PubMed: 22304681]
71. ACOG Practice Bulletin No. 119: Female sexual dysfunction. *Obstet Gynecol.* 2011; 117(4):996–1007. [PubMed: 21422879]
72. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. *N Engl J Med.* 2008; 359(19):2005–17. [PubMed: 18987368]
73. Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertil Steril.* 2007; 88(1):1–17. [PubMed: 17493618]
74. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. *J Sex Med.* 2007; 4(4 Pt 1):859–66. [PubMed: 17627735]
75. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA.* 2013; 310(17):1829–36. [PubMed: 24193080]

76. Jones TH, Channer KS. Deaths and cardiovascular events in men receiving testosterone. *JAMA*. 2014; 311(9):962–3. [PubMed: 24595784]
77. Katz J, Nadelberg R. Deaths and cardiovascular events in men receiving testosterone. *JAMA*. 2014; 311(9):963. [PubMed: 24595786]
78. Riche DM, Baker WL, Koch CA. Deaths and cardiovascular events in men receiving testosterone. *JAMA*. 2014; 311(9):963–4. [PubMed: 24595785]
79. Morgentaler A, Traish A, Kacker R. Deaths and cardiovascular events in men receiving testosterone. *JAMA*. 2014; 311(9):961–2. [PubMed: 24595783]
80. Cappelletti M, Wallen K. Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens. *Horm Behav*. 2015; 78:178–93. [PubMed: 26589379]
81. Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. *Menopause*. 2014; 21(6):612–23. [PubMed: 24281237]
82. Gass ML, Stuenkel CA, Utian WH, LaCroix A, Liu JH, Shifren JL. Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey. *Menopause*. 2015; 22(12):1276–85. [PubMed: 26382314]
83. The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause*. 2012; 19(3):257–71. [PubMed: 22367731]
84. Moynihan R. The making of a disease: female sexual dysfunction. *BMJ*. 2003; 326(7379):45–7. [PubMed: 12511464]
85. Moynihan R. The marketing of a disease: female sexual dysfunction. *BMJ*. 2005; 330(7484):192–4. [PubMed: 15661785]
86. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. *PLoS Med*. 2006; 3(4):e178. [PubMed: 16597176]
87. Jutel A. Framing disease: the example of female hypoactive sexual desire disorder. *Soc Sci Med*. 2010; 70(7):1084–90. [PubMed: 20116160]
88. Brotto LA, Heiman JR, Goff B, Greer B, Lentz GM, Swisher E, et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. *Arch Sex Behav*. 2008; 37(2):317–29. [PubMed: 17680353]
89. Brotto LA, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. *Gynecol Oncol*. 2012; 125(2):320–5. [PubMed: 22293042]
90. Brotto LA, Basson R, Carlson M, Zhu C. Impact of an integrated mindfulness and cognitive behavioural treatment for provoked vestibulodynia (IMPROVED): A qualitative study. *Sexual and Relationship Therapy*. 2013; 28(1-2):3–19.
91. Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. *J Sex Med*. 2008; 5(7):1646–59. [PubMed: 18507718]
92. Brotto LA, Basson R, Smith KB, Driscoll M, Sandownik L. Mindfulness-based group therapy for women with provoked vestibulodynia. *Mindfulness*. 2014; 1:16.
93. Rust J, Golombok S. The GRISS: a psychometric instrument for the assessment of sexual dysfunction. *Arch Sex Behav*. 1986; 15(2):157–65. [PubMed: 3718204]
94. Taylor JF, Rosen RC, Leiblum SR. Self-report assessment of female sexual function: psychometric evaluation of the Brief Index of Sexual Functioning for Women. *Arch Sex Behav*. 1994; 23(6): 627–43. [PubMed: 7872859]
95. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. *Psychopharmacol Bull*. 1997; 33(4):731–45. [PubMed: 9493486]
96. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). *Psychopharmacol Bull*. 1997; 33(4):747–53. [PubMed: 9493487]
97. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther*. 2000; 26(2):191–208. [PubMed: 10782451]

98. Dennerstein L, Anderson-Hunt M, Dudley E. Evaluation of a short scale to assess female sexual functioning. *J Sex Marital Ther.* 2002; 28(5):389–97. [PubMed: 12378841]
99. Quirk FH, Heiman JR, Rosen RC, Laan E, Smith MD, Boolell M. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. *J Womens Health Gen Based Med.* 2002; 11(3):277–89. [PubMed: 11988137]
100. Rosen RC, Lobo RA, Block BA, Yang HM, Zipfel LM. Menopausal Sexual Interest Questionnaire (MSIQ): a unidimensional scale for the assessment of sexual interest in postmenopausal women. *J Sex Marital Ther.* 2004; 30(4):235–50. [PubMed: 15205062]
101. McHorney CA, Rust J, Golombok S, Davis S, Bouchard C, Brown C, et al. Profile of Female Sexual Function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. *Menopause.* 2004; 11(4):474–83. [PubMed: 15243286]
102. Weinfurt KP, Lin L, Bruner DW, Cyranowski JM, Dombek CB, Hahn EA, et al. Development and Initial Validation of the PROMIS((R)) Sexual Function and Satisfaction Measures Version 2.0. *J Sex Med.* 2015; 12(9):1961–74. [PubMed: 26346418]
103. Embreston, SE.; Reise, SP. Item response theory for psychologists. Lawrence Erlbaum Associates; Mahwah, New Jersey: 2000.
104. Revicki DA, Cella DF. Health status assessment for the twenty-first century: item response theory, item banking and computer adaptive testing. *Qual Life Res.* 1997; 6(6):595–600. [PubMed: 9330558]
105. George LK, Weiler SJ. Sexuality in middle and late life. The effects of age, cohort, and gender. *Arch Gen Psychiatry.* 1981; 38(8):919–23. [PubMed: 7259426]
106. Hallstrom T, Samuelsson S. Changes in women's sexual desire in middle life: the longitudinal study of women in Gothenburg. *Arch Sex Behav.* 1990; 19(3):259–68. [PubMed: 2360875]
107. Koster A, Garde K. Sexual desire and menopausal development. A prospective study of Danish women born in 1936. *Maturitas.* 1993; 16(1):49–60. [PubMed: 8429803]
108. Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? *Menopause.* 2000; 7(5):297–309. [PubMed: 10993029]
109. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. *Climacteric.* 2004; 7(4):375–89. [PubMed: 15799609]
110. Dennerstein L, Lehert P. Modeling mid-aged women's sexual functioning: a prospective, population-based study. *J Sex Marital Ther.* 2004; 30(3):173–83. [PubMed: 15205073]
111. Dennerstein L, Lehert P, Burger H. The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition. *Fertil Steril.* 2005; 84(1): 174–80. [PubMed: 16009174]
112. Dennerstein L, Lehert P, Burger H, Dudley E. Factors affecting sexual functioning of women in the mid-life years. *Climacteric.* 1999; 2(4):254–62. [PubMed: 11910659]
113. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? *Fertil Steril.* 2001; 76(3):456–60. [PubMed: 11532464]
114. Mishra G, Kuh D. Sexual functioning throughout menopause: the perceptions of women in a British cohort. *Menopause.* 2006; 13(6):880–90. [PubMed: 17003739]
115. Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M. Hormones and sexuality during transition to menopause. *Obstet Gynecol.* 2007; 109(4):831–40. [PubMed: 17400843]
116. Avis NE, Brockwell S, Randolph JF Jr, Shen S, Cain VS, Ory M, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. *Menopause.* 2009; 16(3):442–52. [PubMed: 19212271]
117. Woods NF, Mitchell ES, Smith-Di Julio K. Sexual desire during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. *J Womens Health (Larchmt).* 2010; 19(2):209–18. [PubMed: 20109116]
118. Prairie BA, Scheier MF, Matthews KA, Chang CC, Hess R. A higher sense of purpose in life is associated with sexual enjoyment in midlife women. *Menopause.* 2011; 18(8):839–44. [PubMed: 21659908]

119. Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, et al. Epidemiology/risk factors of sexual dysfunction. *J Sex Med.* 2004; 1(1):35–9. [PubMed: 16422981]
120. van Lankveld JJ, Grotjohann Y. Psychiatric comorbidity in heterosexual couples with sexual dysfunction assessed with the composite international diagnostic interview. *Arch Sex Behav.* 2000; 29(5):479–98. [PubMed: 10983251]
121. Mitchell KR, Mercer CH, Ploubidis GB, Jones KG, Datta J, Field N, et al. Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). *Lancet.* 2013; 382(9907):1817–29. [PubMed: 24286787]
122. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. *JAMA.* 1999; 281(6):537–44. [PubMed: 10022110]
123. Lutfey KE, Link CL, Litman HJ, Rosen RC, McKinlay JB. An examination of the association of abuse (physical, sexual, or emotional) and female sexual dysfunction: results from the Boston Area Community Health Survey. *Fertil Steril.* 2008; 90(4):957–64. [PubMed: 18023433]
124. Erol B, Tefekli A, Ozbey I, Salman F, Dincag N, Kadioglu A, et al. Sexual dysfunction in type II diabetic females: a comparative study. *J Sex Marital Ther.* 2002; 28(Suppl 1):55–62. [PubMed: 11898710]
125. Enzlin P, Mathieu C, Van den Bruel A, Bosteels J, Vanderschueren D, Demyttenaere K. Sexual dysfunction in women with type 1 diabetes: a controlled study. *Diabetes Care.* 2002; 25(4):672–7. [PubMed: 11919123]
126. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. *Lancet.* 2007; 369(9560):512–25. [PubMed: 17292771]
127. Hulter BM, Lundberg PO. Sexual function in women with advanced multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 1995; 59(1):83–6. [PubMed: 7608715]
128. Korpelainen JT, Nieminen P, Myllyla VV. Sexual functioning among stroke patients and their spouses. *Stroke.* 1999; 30(4):715–9. [PubMed: 10187867]
129. Manolis A, Doumas M. Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. *J Hypertens.* 2008; 26(11):2074–84. [PubMed: 18854743]
130. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. *J Urol.* 2000; 163(2):460–3. [PubMed: 10647654]
131. Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. *J Hypertens.* 2006; 24(12):2387–92. [PubMed: 17082720]
132. Carey JC. Pharmacological effects on sexual function. *Obstet Gynecol Clin North Am.* 2006; 33(4):599–620. [PubMed: 17116504]
133. Van Thiel DH, Gavaler JS, Eagon PK, Chiao YB, Cobb CF, Lester R. Alcohol and sexual function. *Pharmacol Biochem Behav.* 1980; 13(Suppl 1):125–9. [PubMed: 7017755]
134. Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. *J Psychoactive Drugs.* 2001; 33(3):223–32. [PubMed: 11718315]
135. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. *Menopause.* 2008; 15(4 Pt 1):661–6. [PubMed: 18698279]
136. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. *Fertil Steril.* 2013; 100(4):916–21. [PubMed: 24011609]
137. Gilbert E, Ussher JM, Perz J. Sexuality after breast cancer: a review. *Maturitas.* 2010; 66(4):397–407. [PubMed: 20439140]
138. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. *Obstet Gynecol Clin North Am.* 2006; 33(4):621–30. ix. [PubMed: 17116505]
139. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys.* 2003; 56(4):937–49. [PubMed: 12829128]

140. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med*. 1999; 340(18):1383–9. [PubMed: 10228188]
141. Thakar R, Manyonda I, Stanton SL, Clarkson P, Robinson G. Bladder, bowel and sexual function after hysterectomy for benign conditions. *Br J Obstet Gynaecol*. 1997; 104(9):983–7. [PubMed: 9307521]
142. Carlson KJ. Outcomes of hysterectomy. *Clin Obstet Gynecol*. 1997; 40(4):939–46. [PubMed: 9429807]
143. Strippoli GF, Vecchio M, Palmer S, De Berardis G, Craig J, Lucisano G, et al. Sexual dysfunction in women with ESRD requiring hemodialysis. *Clin J Am Soc Nephrol*. 2012; 7(6):974–81. [PubMed: 22490876]
144. Palmer BF. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. *Adv Ren Replace Ther*. 2003; 10(1):48–60. [PubMed: 12616463]
145. Peng YS, Chiang CK, Kao TW, Hung KY, Lu CS, Chiang SS, et al. Sexual dysfunction in female hemodialysis patients: a multicenter study. *Kidney Int*. 2005; 68(2):760–5. [PubMed: 16014053]
146. Salonia A, Zanni G, Nappi RE, Briganti A, Deho F, Fabbri F, et al. Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. *Eur Urol*. 2004; 45(5):642–8. discussion 8. [PubMed: 15082208]
147. Handa VL, Harvey L, Cundiff GW, Siddique SA, Kjerulff KH. Sexual function among women with urinary incontinence and pelvic organ prolapse. *Am J Obstet Gynecol*. 2004; 191(3):751–6. [PubMed: 15467535]
148. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol*. 2009; 29(3):259–66. [PubMed: 19440080]
149. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. *Ann Pharmacother*. 2002; 36(10):1577–89. [PubMed: 12243609]
150. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. *J Clin Psychiatry*. 2002; 63(4):357–66. [PubMed: 12000211]
151. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiocchi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. *J Clin Psychiatry*. 2000; 61(4):276–81. [PubMed: 10830148]
152. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. *J Clin Psychiatry*. 2001; 62(Suppl 3):10–21. [PubMed: 11229449]
153. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. *Clin Pharmacol Ther*. 1997; 61(4):476–87. [PubMed: 9129565]
154. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. *Clin Ther*. 1999; 21(4):643–58. [PubMed: 10363731]
155. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. *Clin Ther*. 2001; 23(7):1040–58. [PubMed: 11519769]
156. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. *Menopause*. 2013; 20(2):162–8. [PubMed: 22990756]
157. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. *Breast*. 2008; 17(5):436–40. [PubMed: 18479922]
158. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. *J Clin Oncol*. 2008; 26(5):753–8. [PubMed: 18258983]
159. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor




- survivors: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2007; 25(19):2792–7. [PubMed: 17602084]
160. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *JAMA.* 1982; 247(12):1707–14. [PubMed: 7038157]
161. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. *Am J Hypertens.* 2004; 17(1):77–81. [PubMed: 14700518]
162. Clark JD, Elliott J. Gabapentin-induced anorgasmia. *Neurology.* 1999; 53(9):2209. [PubMed: 10599814]
163. Newman LC, Broner SW, Lay CL. Reversible anorgasmia with topiramate therapy for migraine. *Neurology.* 2005; 65(8):1333–4. [PubMed: 16247079]
164. Morrell MJ, Flynn KL, Done S, Flaster E, Kalayjian L, Pack AM. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. *Epilepsy Behav.* 2005; 6(3):360–5. [PubMed: 15820344]
165. Lydiard RB, Howell EF, Laraia MT, Ballenger JC. Sexual side effects of alprazolam. *Am J Psychiatry.* 1987; 144(2):254–5. [PubMed: 3812806]
166. Ghadirian AM, Annable L, Belanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. *Am J Psychiatry.* 1992; 149(6):801–5. [PubMed: 1590497]
167. Hawton K, Catalan J, Fagg J. Low sexual desire: sex therapy results and prognostic factors. *Behav Res Ther.* 1991; 29(3):217–24. [PubMed: 1883302]
168. Schover LR, LoPiccolo J. Treatment effectiveness for dysfunctions of sexual desire. *J Sex Marital Ther.* 1982; 8(3):179–97. [PubMed: 7143457]
169. McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. *J Sex Marital Ther.* 2001; 27(3):259–71. [PubMed: 11354931]
170. Trudel G, Marchand A, Ravart M, Aubin S, Turgeon L, Fortier P. The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. *Sexual and Relationship Therapy.* 2001; 16(2):145–64.
171. Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. *J Sex Med.* 2008; 5(7):1646–59. [PubMed: 18507718]
172. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. *BJOG.* 2003; 110(11):1014–24. [PubMed: 14592587]
173. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, et al. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. *J Sex Med.* 2011; 8(11):3160–72. [PubMed: 21933348]
174. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr. et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. *J Sex Med.* 2012; 9(3):793–804. [PubMed: 22239862]
175. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr. et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. *J Sex Med.* 2012; 9(4):1074–85. [PubMed: 22248038]
176. Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr. et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. *J Sex Med.* 2013; 10(7):1807–15. [PubMed: 23672269]
177. McMullen S, Rosen RC. Self-administered masturbation training in the treatment of primary orgasmic dysfunction. *J Consult Clin Psychol.* 1979; 47(5):912–8. [PubMed: 574521]
178. Barbach LG. Group treatment of preorgasmic women. *J Sex Marital Ther.* 1974; 1(2):139–45. [PubMed: 4470125]
179. Heiman, J.; LoPiccolo, J. *Becoming orgasmic: A sexual and personal growth program for women.* Simon and Schuster; New York, NY: 1987.
180. LoPiccolo J, Lobitz WC. The role of masturbation in the treatment of orgasmic dysfunction. *Archiv Sex Behav.* 1972; 2:163–71.


181. Masters, WH.; Johnson, VE. Human sexual inadequacy. Churchill; London: 1970.
182. Wolpe, J. Psychotherapy by reciprocal inhibition. Stanford University Press; Stanford, CA: 1958.
183. Billups KL. The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. *World J Urol.* 2002; 20(2):137–41. [PubMed: 12107545]
184. Brotto LA, Basson R, Carlson M, Zhu C. Impact of an integrated mindfulness and cognitive behavioural treatment for provoked vestibulodynia (IMPROVED): A qualitative study. *Sexual and Relationship Therapy.* 2013; 28(1-2):3–19.
185. Brotto LA, Basson R, Smith KB, Driscoll M, Sandownik L. Mindfulness-based group therapy for women with provoked vestibulodynia. *Mindfulness.* 2014:1–16.
186. Glazer HI, Rodke G, Swencionis C, Hertz R, Young AW. Treatment of vulvar vestibulitis syndrome with electromyographic biofeedback of pelvic floor musculature. *J Reprod Med.* 1995; 40(4):283–90. [PubMed: 7623358]
187. McKay E, Kaufman RH, Doctor U, Berkova Z, Glazer H, Redko V. Treating vulvar vestibulitis with electromyographic biofeedback of pelvic floor musculature. *J Reprod Med.* 2001; 46(4): 337–42. [PubMed: 11354833]
188. Bergeron S, Brown C, Lord MJ, Oala M, Binik YM, Khalife S. Physical therapy for vulvar vestibulitis syndrome: a retrospective study. *J Sex Marital Ther.* 2002; 28(3):183–92. [PubMed: 11995597]
189. Bergeron S, Binik YM, Khalife S, Pagidas K, Glazer HI, Meana M, et al. A randomized comparison of group cognitive--behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. *Pain.* 2001; 91(3):297–306. [PubMed: 11275387]
190. Danielsson I, Torstensson T, Brodda-Jansen G, Bohm-Starke N. EMG biofeedback versus topical lidocaine gel: a randomized study for the treatment of women with vulvar vestibulitis. *Acta Obstet Gynecol Scand.* 2006; 85(11):1360–7. [PubMed: 17091418]
191. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. *J Sex Med.* 2005; 2(Suppl 3):154–65. [PubMed: 16422792]
192. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. *Fertil Steril.* 2006; 85(1):155–60. [PubMed: 16412747]
193. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. *Menopause.* 2013; 20(6):623–30. [PubMed: 23361170]
194. Munday PE. Response to treatment in dysaesthetic vulvodynia. *J Obstet Gynaecol.* 2001; 21(6): 610–3. [PubMed: 12521781]
195. Bergeron S, Bouchard C, Fortier M, Binik YM, Khalife S. The surgical treatment of vulvar vestibulitis syndrome: a follow-up study. *J Sex Marital Ther.* 1997; 23(4):317–25. [PubMed: 9427210]
196. Kehoe S, Luesley D. Vulvar vestibulitis treated by modified vestibulectomy. *Int J Gynaecol Obstet.* 1999; 64(2):147–52. [PubMed: 10189023]
197. Goetsch MF. Simplified surgical revision of the vulvar vestibule for vulvar vestibulitis. *Am J Obstet Gynecol.* 1996; 174(6):1701–5. [PubMed: 8678130]
198. Bohm-Starke N, Rylander E. Surgery for localized, provoked vestibulodynia: a long-term follow-up study. *J Reprod Med.* 2008; 53(2):83–9. [PubMed: 18357798]
199. Goldstein AT, Klingman D, Christopher K, Johnson C, Marinoff SC. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. *J Sex Med.* 2006; 3(5):923–31. [PubMed: 16942537]

### Highlights


- Sex is an important component of overall well-being, but sexual dysfunction is common in midlife women.
- A holistic, biopsychosocial approach is necessary to guide research and clinical care regarding women's sexual function.
- Longitudinal studies reveal an association between advancing menopause status and worsening sexual function.
- Future research should focus on understanding changes in sexual function with aging and developing treatments for sexual dysfunction in midlife and older women.




**Figure 1.**  
Masters-Johnson Model of Sexual Response  
Adapted from Masters WH JV. Human Sexual Response. Boston: Little, Brown & Co;  
1966.



**Figure 2.**  
Masters-Johnson-Kaplan Model of Sexual Response  
Adapted from Kaplan HS. Disorders of Sexual Desire: Simon and Schuster; 1979.



**Figure 3.**  
Basson Model of Female Sexual Response  
Adapted from Basson R. The female sexual response: a different model. *Journal of sex & marital therapy*. 2000;26(1):51-65.



**Figure 4.** Biopsychosocial Model of Female Sexual Function  
 Adapted from Rosen RC, Barsky JL. Normal sexual response in women. *Obstetrics and gynecology clinics of North America*. 2006;33(4):515-26 and Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe M, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. *The journal of sexual medicine*. 2005;2(6):793-800.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

## Measurement tools for female sexual function and dysfunction

Scale name	Citation	Number of items	Domains	Validity evidence
Golombok Rust Inventory of Sexual Satisfaction (GRISS)	Rust, <i>Archives of Sexual Behavior</i> , 1986 (1)	28	Anorgasmia, vaginismus, noncommunication, infrequency, avoidance, nonsensuality, dissatisfaction	Discriminatory validity $r = 0.63$ Agreement with therapist blind ratings = 0.54
Brief Index of Sexual Functioning – Women (BISF-W)	Taylor, <i>Archives of Sexual Behavior</i> , 1994 (2)	22	interest/desire, sexual activity, satisfaction	Overall alpha = 0.83 Test-retest $r = 0.68-0.78$
Changes in Sexual Functioning Questionnaire (CSFQ)	Clayton, <i>Psychopharmacology</i> , 1997 (3, 4)	14	Pleasure, desire/frequency, desire/interest, arousal/excitement, orgasm/completion	Test-retest $r = 0.45 - 1.00$
Female Sexual Function Index (FSFI)	Rosen, <i>Journal of Sexual Medicine</i> , 2000 (5)	19	Desire, arousal, lubrication, orgasm, satisfaction, pain	Test-retest for domains $r = 0.79-0.86$ Internal consistency alpha 0.82 and higher
Short Form – Personal Experiences Questionnaire (SPEQ)	Dennerstein, <i>Sex &amp; Marital Therapy</i> , 2002 (6)	9	Sexual responsivity, sexual frequency, libido	Test-retest for domains $r = 0.71-0.95$
Sexual Functioning Questionnaire (SFQ)	Quirk, <i>Journal of Women's Health &amp; Gender-Based Medicine</i> , 2002 (7)	31	Desire, physical arousalsensation, physical arousal-lubrication, enjoyment, orgasm, pain, partner relationship	Internal consistency domains = 0.65=0.91 Test-retest = 0.21-0.71
Menopause Sexual Interest Questionnaire (MSIQ)	Rosen, <i>Sex &amp; Marital Therapy</i> , 2004 (8)	10	Desire, responsiveness, satisfaction	Internal consistency alpha 0.87 and higher Test-retest for domains $r = 0.52-0.76$
Profile of Female Sexual Function (PFSF)	McHorney, <i>Menopause</i> , 2004 (9)	37	Sexual pleasure, sexual desire, responsiveness, arousal, orgasm, sexual self image, sexual concerns, disinterest	Alpha 0.79-0.96 Test-retest 0.57-0.91
PROMIS Sexual Function and Satisfaction Scale	Weinfurt, <i>Journal of Sexual Medicine</i> , 2015 (10)	Varies, as uses item-response theory (11) and computer-adaptive testing (12)	Satisfaction with sex life, interest in sexual activity, vaginal lubrication, vaginal discomfort, orgasm-pleasure, orgasm-ability, vulvar discomfort, oral discomfort, oral dryness	Cronbach's alpha 0.85-0.97



Table 2

## Longitudinal studies of sexual function during midlife

Reference	Study details	Sexual function measure	Key findings
George & Weiler, 1981 (13)	N=278 men and women Age 46-71 at baseline 4 interviews 2 years apart	Only used 2 questions to evaluate sexual function	<ul style="list-style-type: none"> <li>Mean sexual activity remained relatively stable over the 6 years of the study, especially among women.</li> </ul>
Hallstrom et al., 1990 (14)	N=497 women Age 38-54 at baseline 2 interviews 6 y apart	Only assessed sexual desire, and with only one question	<ul style="list-style-type: none"> <li>The majority of women reported no decrease in sexual desire between the two interviews.</li> <li>Lower desire was associated with poor relationship quality, partner alcoholism, and depression.</li> <li>No demographic variables were associated with lower desire.</li> </ul>
Koster & Garde, 1993 (15)	N=474 women Age 40 at baseline 3 interviews, 5 years apart	No validated instrument used to assess sexual function	<ul style="list-style-type: none"> <li>70% of women experienced no change in desire during the study period.</li> <li>Menopause status was not related to frequency or change in sexual desire.</li> <li>Health status, prior sexual activity, partner availability, and social status were highly related to frequency of sexual desire.</li> <li>Anticipations of declining desire due to menopause predicted a decrease.</li> </ul>
Avis et al., 2000 (16)	N=200 women Age 45-55 at baseline Yearly interviews for 4 years	Multidimensional, but unvalidated, measure of sexual function	<ul style="list-style-type: none"> <li>Advancing menopause status was significantly related to lower sexual desire.</li> <li>Advancing menopause status was unrelated to other aspects of sexual functioning, including satisfaction, frequency of intercourse, arousal, orgasm, and pain.</li> <li>Health, marital status, and mental health had a greater impact on sexual function than menopause status.</li> </ul>
Guthrie et al., 2004 (17) Dennerstein et al., 2004 (18) Dennerstein et al., 2005 (19) Dennerstein et al., 1999 (20) Dennerstein et al., 2001 (21)	N=197 women Age 45-55 at baseline Annual interviews over 9 years	Used short form Personal Experiences Questionnaire (SPEQ)	<ul style="list-style-type: none"> <li>Sexual function declines during the menopause transition in all domains.</li> <li>Partner feelings, responsivity, and partner problems decrease in early menopause.</li> <li>Responsivity, frequency, libido, dyspareunia, and partner problems decrease in later menopause.</li> <li>Among women who were postmenopausal during the entire study period, the only domain that changes was responsivity, suggesting aging affects all domains, but menopause affects only responsivity.</li> <li>Worsening sexual function was correlated with decreasing estrogen but not decreasing androgen.</li> <li>Prior sexual function, partner status, and feelings towards partner are the most important determinants to sexual function.</li> </ul>
Mishra et al., 2006 (22)	N=1525 women Age 47-54 at baseline Annual interviews over 8 years	Only used 2 questions to assess sexual function	<ul style="list-style-type: none"> <li>Compared to women who remained premenopausal, women who became peri- and postmenopausal had selfperceived declines in sexual function, even when accounting for aging and other factors.</li> <li>A majority of women report no change in sex life year to year.</li> <li>Vaginal dryness is a major risk factor for perceived decline in sex function.</li> <li>Hot flashes are associated with intercourse difficulties.</li> </ul>

Reference	Study details	Sexual function measure	Key findings
			<ul style="list-style-type: none"> <li>Stress, aging, smoking, mood symptoms were associated with a self-perceived decline in sex life.</li> </ul>
Gracia et al., 2007 (23)	N=436 Age 35-47 at baseline Annual assessments over 3 years	Used the Female Sexual Function Index (FSFI)	<ul style="list-style-type: none"> <li>Higher DHEAS is associated with better sexual function in the domains of orgasm, lubrication, and pain.</li> <li>Advancing menopause status is associated with worse sexual function.</li> <li>Lack of a sexual partner is associated with worse sexual function in all domains.</li> <li>Having children in the house is associated with worse arousal, orgasm, and satisfaction.</li> <li>Higher anxiety is associated with worse sexual function in all domains.</li> <li>Age, race, and education are not significantly related to sexual function.</li> <li>Other hormones (testosterone, estradiol, FSH) are not significantly related to sexual function.</li> </ul>
Avis et al., 2009 (24)	N=3302 women Age 42-52 at baseline Annual assessments over 6 years	Multidimensional, but unvalidated, measure of sexual function	<ul style="list-style-type: none"> <li>Menopause status is associated with decreasing desire and increasing vaginal pain, even when adjusting for age and other factors.</li> <li>Menopause status was NOT associated with frequency of sex, arousal, importance of sex, emotional satisfaction, or physical pleasure.</li> <li>Vaginal dryness had a negative effect on many aspects of sexual function.</li> <li>Age, importance of sex, education, marital status, change in relationship status, attitudes towards aging, mood symptoms, health status, and race were all related to sexual function.</li> </ul>
Woods et al., 2010 (25)	N=286 women Mean age 41.4 at baseline Annual questionnaires from beginning of study until 5 years postmenopause	Assessed only sexual desire in the prior 24 hours with a single question	<ul style="list-style-type: none"> <li>Desire decreased significantly during late per menopause and early post menopause.</li> <li>Higher urinary estrogen byproducts and testosterone were associated with higher sexual desire.</li> <li>Higher FSH was associated with lower sexual desire. • Higher stress was associated with lower sexual desire.</li> <li>Menopause symptoms (vasomotor, mood, insomnia) were associated with lower desire.</li> <li>Better self-perceived health was associated with higher desire.</li> <li>Having a partner was associated with lower desire.</li> </ul>
Prairie et al., 2011 (26)	N=459 women Ages 40-65 at baseline Annual questionnaires over 3 years	Multidimensional, but unvalidated, measure of sexual function	<ul style="list-style-type: none"> <li>Higher life purpose was associated with higher sexual enjoyment.</li> <li>Younger age, more social support, and higher emotional well-being was associated with more engagement in sexual activities.</li> <li>Higher social support and better emotional well-being were associated with higher enjoyment of sex.</li> <li>Menopause status was not associated with engagement or enjoyment in sexual activities.</li> </ul>

**Table 3**

Medical and psychiatric conditions that are associated with female sexual dysfunction

Cardiovascular disease (27)
Major depressive disorder and generalized anxiety disorder (28, 29)
History of emotional, physical, or sexual abuse (30, 31)
Diabetes mellitus (32, 33)
Neurologic disease (stroke, multiple sclerosis, spinal cord injury) (34-36)
Hypertension (37-39)
Substance use disorders (40-42)
Genitourinary syndrome of menopause (22, 24, 43)
Breast, ovarian, uterine, and cervical cancer (44-48)
History of gynecologic surgery (49, 50)
Chronic renal failure (51-53)
Urinary incontinence (54, 55)
<b>Medications that are associated with female sexual dysfunction</b>
Antidepressants (selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants) (56-63)
Opiates (42)
Cancer therapies, especially for breast and gynecologic cancer (44, 64-67)
Antihypertensives (mixed evidence), particularly beta-blockers (68) (69)
Antiepileptics, particularly gabapentin (70), topiramate (71), and phenytoin (72)
Benzodiazepines (73, 74)

**Table 4**

## Treatment options for female sexual dysfunctions

Disorder	Treatment options	Considerations
Female sexual interest / arousal disorder	Psychological and behavioral interventions	There is evidence for modified Masters and Johnson treatment (75), behavioral sex therapy (76), cognitivebehavioral therapy (77, 78), and mindfulness-based approaches(79, 80)
	Flibanserin	It is only approved by the Food and Drug Administration (FDA) for the treatment of hypoactive sexual desire disorder in <b>premenopausal</b> women. The clinical effects are somewhat limited, there are notable side effects and medication interactions, and women taking the medication cannot use alcohol.(81-84)
Female orgasmic disorder	Psychological and behavioral interventions	There is evidence for directed masturbation (85-88) and sensate focus. Anxiety reduction techniques (systematic desensitization, cognitive behavioral therapy) if anxiety is co-occurring (89, 90).
	Sexual aids, such as vibrators(91)	
Genito-pelvic pain / penetration disorder	Psychological and behavioral interventions	There is evidence for mindfulness-based approaches (92, 93) and cognitive-behavioral therapy/biofeedback (94-98)
	Treatment of genitourinary syndrome of menopause, if present (i.e., vaginal estrogen, ospemifene)(99-101)	
	Pelvic floor physical therapy(96)	It must be conducted by a specially-trained physical therapist.
	Topical lidocaine(98)	It often causes burning when first applied.
	Tricyclic antidepressants(102)	These can interact with other medications and cause sleepiness, dry mouth, or urinary retention (the latter more common in older patients).
	Vestibulectomy	There are high reported success rates, but it is usually not performed until less invasive treatments have failed.(103-107)